Immunogenicity, toxicology, pharmacokinetics and pharmacodynamics of growth hormone ligand-receptor fusions

Clinical Science

Volumn 119, Issue 11, 2010, Pages 483-491

  Ferrandis, Eric ^a   Pradhananga, Sarbendra L ^b   Touvay, Caroline ^a   Kinoshita, Carol ^c   Wilkinson, Ian R ^b   Stafford, Kevin ^c   Wu, Zida ^d   Strasburger, Christian J ^d   Sayers, Jon R ^b   Artymiuk, Peter J ^b   Ross, Richard J ^b  

^a Institut Henri Beaufour   (France)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c Biomeasure Inc   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Growth Hormone (GH); Immunogenicity; Ligand; Pharmacodynamics; Pharmacokinetics; Receptor fusion; Toxicity

Indexed keywords

ANTIGEN; GROWTH HORMONE LIGAND RECEPTOR FUSION PROTEIN; GROWTH HORMONE RECEPTOR; HYBRID PROTEIN; LIGAND; RECOMBINANT GROWTH HORMONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LIGAND BINDING; MACACA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN VARIANT; RAT; WEIGHT GAIN;

ANIMALS; ANTIBODY FORMATION; DRUG EVALUATION, PRECLINICAL; GROWTH HORMONE; LIGANDS; MACACA FASCICULARIS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SOMATOTROPIN; RECOMBINANT FUSION PROTEINS;

EID: 78649807944     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20100241     Document Type: Article

References (33)

1. Wilkinson, I. R., Ferrandis, E., Artymiuk, P. J., Teillot, M., Soulard, C., Touvay, C., Pradhananga, S. L., Justice, S., Wu, Z., Leung, K. C. et al. (2007) A ligand-receptor fusion of growth hormone forms a dimer and is a potent long-acting agonist. Nat. Med. 13, 1108-1113
2. Huston, J. S., Tai, M. S., McCartney, J., Keck, P. and Oppermann, H. (1993) Antigen recognition and targeted delivery by the single-chain Fv. Cell. Biophys. 22, 189-224
3. de Vos, A. M., Ultsch, M. and Kossiakoff, A. A. (1992) Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255, 306-312
4. Schellekens, H. and Casadevall, N. (2004) Immunogenicity of recombinant proteins: causes and consequences. J. Neurol. 251, 114-119
5. Frasier, S. D. (1983) Human pituitary growth hormone (hGH) therapy in growth hormone deficiency. Endocr. Rev. 4, 155-170
6. Gunnarsson, R. and Wilton, P. (1987) Clinical experience with Genotropin worldwide: an update March 1987. Acta Paediatr. Scand. Suppl. 337, 147-152
7. Job, J. C., Rochiccioli, P., Rappaport, R., Raux-Demay, M. C., Ponte, C., Juif, J., Colle, M., Lecornu, M., Leheup, B. and Garandeau, P. (1988) 1-year treatment with recombinant somatropin in prepubertal and pubertal growth hormone deficient patients: results from a French multicentre trial. Acta Paediatr. Scand. Suppl. 347, 187-190
8. Takano, K., Shizume, K., Hibi, I., Okuno, A., Hanyu, K., Suwa, S., Nakajima, H., Kondo, T., Kato, K., Iwatani, N. et al. (1988) Treatment of hypopituitarism with recombinant somatropin for 1 year. Acta Paediatr. Scand. Suppl. 347, 169-175
9. Buzi, F., Buchanan, C. R., Morrell, D. J. and Preece, M. A. (1989) Antigenicity and efficacy of authentic sequence recombinant human growth hormone (somatropin): first-year experience in the United Kingdom. Clin. Endocrinol. 30, 531-538
10. Chang, T. C., Kuo, H. F., Liu, P. C., Shih, K. C., Zeisel, H. J. and Ho, L. T. (1991) Recombinant DNA produced somatropin in the treatment of prepubertal growth hormone deficient children. Zhonghua Yi Xue Za Zhi 47, 7-12
11. Rougeot, C., Marchand, P. M., Dray, F., Girard, F., Job, J. C., Pierson, M., Ponte, C., Rochiccioli, P. and Rappaport, R. (1991) Comparative study of biosynthetic human growth hormone immunogenicity in growth hormone deficient children. Horm. Res. 35, 76-81
12. Lundin, K., Berger, L., Blomberg, F. and Wilton, P. (1991) Development of anti-GH antibodies during therapy with authentic human growth hormone. Acta Paediatr. Scand. Suppl. 372, 167-168
13. Massa, G., Vanderschueren-Ledeweyckx, M. and Bouillon, R. (1993) Five-year follow-up of growth hormone antibodies in growth hormone deficient children treated with recombinant human growth hormone. Clin. Endocrinol. 38, 137-142
14. Shih, K. C., Ho, L. T., Kuo, H. F., Chang, T. C., Liu, P. C., Chen, C. K. and Tiu, C. M. (1994) Linear growth response to recombinant human growth hormone in children with growth hormone deficiency. Zhonghua Yi Xue Za Zhi 54, 7-13
15. Pirazzoli, P., Cacciari, E., Mandini, M., Cicognani, A., Zucchini, S., Sganga, T. and Capelli, M. (1995) Follow-up of antibodies to growth hormone in 210 growth hormone-deficient children treated with different commercial preparations. Acta Paediatr. 84, 1233-1236
16. Li, S., Yu, Y., An, Z., Xiong, Z. and Yu, H. (2002) The immunogenicity and effect of domestic recombinant human growth hormone: serum GH-antibody determination and evaluation. Hua Xi Yi Ke Da Xue Xue Bao 33, 77-79
17. Jones, A. J. (2002) The use of an animal immunogenicity model in the development of Protropin somatrem (methionyl human growth hormone). Dev. Biol. 109, 107-118
18. Lee, H. J., Riley, G., Johnson, O., Cleland, J. L., Kim, N., Charnis, M., Bailey, L., Duenas, E., Shahzamani, A., Marian, M., Jones, A. J. S. and Putney, S. D. (1997) In vivo characterization of sustained-release formulations of human growth hormone. J. Pharmacol. Exp. Ther. 281, 1431-1439
19. Zwickl, C. M., Cocke, K. S., Tamura, R. N., Holzhausen, L. M., Brophy, G. T., Bick, P. H. and Wierda, D. (1991) Comparison of the immunogenicity of recombinant and pituitary human growth hormone in rhesus monkeys. Fund. Appl. Toxicol. 16, 275-287
20. Covic, A. and Kuhlmann, M. K. (2007) Biosimilars: recent developments. Int. Urol. Nephrol. 39, 261-266
21. Trainer, P. J., Drake, W. M., Katznelson, L., Freda, P. U., Herman-Bonert, V., Van der Lely, A. J., Dimaraki, E. V., Stewart, P. M., Friend, K. E., Vance, M. L. et al. (2000) Treatment of acromegaly with the growth hormone-receptor antagonist Pegvisomant. New Engl. J. Med. 342, 1171-1177
22. Hodish, I. and Barkan, A. (2008) Long-term effects of pegvisomant in patients with acromegaly. Nat. Clin. Pract. 4, 324-332
23. Silverman, B. L., Blethen, S. L., Reiter, E. O., Attie, K. M., Neuwirth, R. B. and Ford, K. M. (2002) A long-acting growth hormone (Nutropin Depot): efficiency and safety following two years of treatment in children with growth hormone deficiency. J. Pediatr. Endocrinol. Metab. 15, 715-722
24. Cook, D. M., Biller, B. M. K., Vance, M. L., Hoffman, A. R., Phillips, L. S., Ford, K. M., Benzinger, D. P., Illeperuma, A., Blethen, S. L., Attie, K. M. et al. (2002) The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (Nutropin Depot) in GH-deficient adults. J. Clin. Endocr. Metab. 87, 4508-4514
25. Touraine, P., D'Souza, G. A., Kourides, I., Abs, R., Barclay, P., Xie, R., Pico, A., Torres-Vela, E. and Ekman, B. (2009) Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH. Eur. J. Endocrinol. 161, 533-540
26. Bernabeu, I., Cameselle-Teijeiro, J., Casanueva, F. F. and Marazuela, M. (2009) Pegvisomant-induced cholestatic hepatitis with jaundice in a patient with Gilbert's syndrome. Eur. J. Endocrinol. 160, 869-872
27. Lou, K.-J. (2009) Growing a PEG-like alternative. SciBX 2, 1-2
28. Yin, D., Vreeland, F., Schaaf, L. J., Millham, R., Duncan, B. A. and Sharma, A. (2007) Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin. Cancer Res. 13, 1000-1009
29. Osborn, B. L., Sekut, L., Corcoran, M., Poortman, C., Sturm, B., Chen, G., Mather, D., Lin, H. L. and Parry, T. J. (2002) Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur. J. Pharmacol. 456, 149-158
30. Mordenti, J., Chen, S. A., Moore, J. A., Ferraiolo, B. L. and Green, J. D. (1991) Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharmaceut. Res. 8, 1351-1359
31. Clark, R., Olson, K., Fuh, G., Marian, M., Mortensen, D., Teshima, G., Chang, S., Chu, H., Mukku, V., Canova-Davis, E. et al. (1996) Long acting growth hormones produced by conjugation with polyethylene glycol. J. Biol. Chem. 271, 21969-21977
32. Pai, S. S., Tilton, R. D. and Przybycien, T. M. (2009) Poly(ethylene glycol)-modified proteins: implications for poly(lactide-co-glycolide)-based microsphere delivery. AAPS J. 11, 88-98
33. Kemp, S. K., Fielder, P. J., Attie, K. M., Blethen, S. L., Reiter, E. O., Ford, K. M., Marian, M., Dao, L. N., Lee, H. J. and Saenger, P. (2004) Pharmacokinetic and pharmacodynamic characteristics of long-acting growth hormone (GH) preparation (Nutropin Depot) in GH-deficient children. J. Clin. Endocr. Metab. 89, 3234-3240